Breathing Disorder Treatment Market is segmented By Drug Class (Antimicrobial, Corticosteroid, Bronchodilator, Antihistamines, Respiratory stimulants, Others), By Indication (Chronic Obstructive Pulmonary Disease (COPD), Asthma, Cystic Fibrosis, Pulmonary Hypertension, Lung Cancer, Allergic Rhinitis, Idiopathic Pulmonary Fibrosis, Others), By Distribution Channel (Hospital Pharmacies, Retail Pharmacies, Online Pharmacies), and By Region (North America, Latin America, Europe, Asia Pacific, Middle East, and Africa) – Share, Size, Outlook, and Opportunity Analysis, 2024-2031
Market Overview
The breathing disorder treatment market size was valued at USD million in 2023 and is estimated to reach USD million by 2030, growing at a CAGR of 4.8% during the forecast period (2024-2031).
Breathing disorder drugs are medications used for treating several respiratory or breathing disorders, such as COPD and asthma. These medicines make breathing easier by reducing inflammation and opening the airways. High exposure to air pollution and dust and increased smoking will enhance the adoption of these drugs.
As per DataM Intelligence, Breathing Disorder Treatment Market study analysis offers an in-depth outlook on the market containing quantitative and qualitative data. It gives an outlook and forecast of the global market based on market segmentation. It also provides global Breathing Disorder Treatment Market size, and growth, along with the latest trends, opportunities, and forecast till 2030 for the global market with esteem to major countries such as the United States, Canada, Brazil, Germany, Italy, Spain, United Kingdom, Russia, European countries, United Arab Emirates, Saudi Arabia, South Africa, Japan, China, India, South Korea, Australia, and rest of the countries over the globe.
Among all regions, the North American region is expected to hold the largest share of the global market over the forecast period. Breathing Disorder Treatment Market in the United States and Canada produces the utmost share. Whereas the European Breathing Disorder Treatment Market is projected to continue its presence globally during the period of 2024-2031.
Market Summary
| Metrics | Details |
| Market CAGR | 4.8% |
| Segments Covered | By Drug Class, By Indication, By Distribution Channel, and By Region |
| Report Insights Covered | Competitive Landscape Analysis, Company Profile Analysis, Market Size, Share, Growth, Demand, Recent Developments, Mergers and acquisitions, New Product Launches, Growth Strategies, Revenue Analysis, and Other key insights. |
| Fastest Growing Region | Asia Pacific |
| Largest Market Share | North America |
To Get a Free Sample Click here
Market Dynamics
The market for breathing disorder treatment is driven by the increase in the number of people with respiratory disorders, including asthma and COPD, rising advanced technology, increasing research and development investments and the rising investment in healthcare infrastructure in emerging markets.
The rising adoption of breathing disorders drugs and increasing investment in research and development are expected to drive the market’s growth.
The breathing disorder treatment market is driven by rising advancements in technology, an increase in demand for breathing disorder drugs, a surge in research and development investments, an increasing number of chronic respiratory disorders such as asthma, COPD, chronic bronchitis, and improvements in novel drugs using the latest technology along with advances in medical infrastructure in emerging markets. According to the WHO, chronic obstructive pulmonary disease (COPD) affects nearly 200 million people globally. Today, rising funding by government organizations for the treatment of chronic diseases will boost the market growth. For instance, in European Union, the direct cost of COPD is around 6% of total health expenditure, accounting for nearly 56% of the total cost of respiratory diseases.
Technological advances have resulted in increasing breathing disorder drugs adoption. The rising number of respiratory disorders, increasing awareness about bronchodilators and antimicrobial drugs for treating respiratory disorders and rising healthcare expenditure by governments and the private sector could lead to higher infrastructure investments and drive the breathing disorder treatment market.
Various novel product launches and research studies contribute to the market’s growth. For instance, in March 14, 2022, Sandoz, a Novartis subsidiary, announced its successful acquisition of Coalesce Product Development Limited, a UK-based drug delivery and medical device development company. Sandoz, with this acquisition, acquired the significant capabilities of Coalesce that can help in building on its existing respiratory medicines portfolio.
The side effects associated with breathing disorder treatment drugs are expected to hamper the market’s growth.
The global market for breathing disorder treatment is restrained by the side effects of drugs for breathing disorder treatment. Side effects include dry mouth, tremors, dizziness, irritated or scratchy throat, runny nose and upset stomach.
Stringent rules and regulations for respiratory disorders treatment drugs approval and adverse events such as trembling, nervous tension, palpitations, muscle cramps, and others associated with bronchodilators hinder the market growth.
COVID-19 Impact Analysis on Market
The pandemic has positively impacted global financial expectations, operations and crisis response strategy. The COVID-19 outbreak has severely affected the healthcare industry. The breathing disorder treatment market has experienced huge profits due to COVID as various research, and clinical trials got started in full swing due to the increasing cases of COVID. Key manufacturers have started various research and clinical trials. Multiple initiatives, product launches, collaborations and mergers are happening worldwide, boosting the market’s growth. For instance, in December 17, 2021, Amgen announced that AstraZeneca and Amgen’s Tezspire (tezepelumab-ekko) had been approved by the U.S. Food and Drug Administration (FDA) for pediatric and adult patients aged 12 years and older, add-on maintenance treatment with severe asthma.
Market Segment Analysis
The bronchodilators segment is expected to grow at the fastest CAGR during the forecast period (2022-2029)
The bronchodilators segment is the highest market holder in the global breathing disorder treatment market. The global breathing disorder treatment market is segmented on the basis of drug class in antimicrobial, corticosteroid, bronchodilator, antihistamines, respiratory stimulants and others. The bronchodilator segment is the largest market shareholder due to its rising adoption and demand due to increased respiratory disorders, technological advancements, and novel product launches.
These drugs are the most used inhaled medications. The bronchodilators can be further divided into parasympatholytic (anticholinergic) drugs and sympathomimetic (adrenergic) drugs and are classified as long-acting or short-acting. Anticholinergic drugs block the parasympathetic system, while adrenergic drugs basically stimulate the sympathetic nervous system. Adrenergic agents cause bronchodilation, and anticholinergic drugs generally block bronchoconstriction. Short-acting bronchodilators are efficacious for 4 to 6 hours, while long-acting drugs generally last about 12 hours.
The growing number of regulatory approvals, technological advancements, product launches, and research/clinical trial studies drive the market’s growth. For instance, in July 7, 2020, Novartis announced that its Enerzair Breezhaler (glycopyrronium bromide, indacaterol acetate, and mometasone furoate) first LABA/long-acting muscarinic antagonist fixed-dose combination had been approved by the European Commission (EC) for asthma treatment in adult patients with a combination of a high-dose of an inhaled corticosteroid (ICS) and long‑acting beta2‑agonist (LABA), who experienced asthma exacerbations.
Market Geographical Share
North America holds the largest market share in the global breathing disorder treatment market.
North America dominates the global breathing disorder treatment market primarily due to its large population, excellent medical infrastructure, and high-income levels. The market is expected to grow at a relatively high pace during the forecast period due to healthcare expenditure in the US. The market’s significant size is attributed to the high medical expenditure. According to the Office of Disease Prevention and Health Promotion (ODPHP), around 14.8 million adults suffered from chronic obstructive pulmonary disease (COPD) in the United States in 2020. And 25 million have asthma.
Increasing expenditure on healthcare and raising awareness among people is also contributing to the market’s growth in this region. Advancement of medications for breathing disorder treatment in asthma, and COPD, increase in pharmaceutical establishment across the region and government approvals, and the presence of key players in the region are contributing to the growth of the breathing disorder treatment market.
Moreover, the growing number of product launches is responsible for the market’s growth. Many key developments, technological advancements, collaborations, and agreements are taking place in this region. For instance, in March 23, 2020, Bayer announced its license agreement and research collaboration with Curadev, a domestic drug discovery firm for discovering novel drug candidates for cardiovascular, lung and inflammatory diseases treatment.
Market Competitive Landscape
The breathing disorder treatment market is highly competitive with local and global companies’ presence. F. Hoffmann-La Roche, AstraZeneca, GSK plc, Abbott Laboratories, Amgen Inc., Novartis AG, Medtronic plc, Dr. Reddy’s Laboratories Ltd., Bayer AG, Biogen and more. The key players are adopting various growth strategies such as product launches, mergers & acquisitions, partnerships, and collaborations, contributing to the market’s growth. For instance, in February 16, 2022, Mankind Pharma announced that it had signed an acquisition agreement with Dr. Reddy's Laboratories for two brands, Daffy and Combihale. Combihale is utilized for treating chronic obstructive pulmonary disease and asthma.
Novartis AG.
Overview: Novartis is engaged in the discovery, development, manufacture, and sale of a wide range of pharmaceutical and generic medicines. The company has two operating divisions globally: Innovative medicines and Sandoz for biosimilars and generic pharmaceuticals.
Product Portfolio:
Arcapta Neohaler: Arcapta Neohaler is the once-daily, 24-hour long-acting beta2-agonist that has been approved for airflow obstruction in COPD patients’ maintenance treatment.
Key Development: In November 19, 2020, Novartis announced its exclusive global collaboration and license agreement with Mesoblast for the development, manufacturing and selling of remestemcel-L for acute respiratory distress syndrome (ARDS) treatment, including that associated with COVID-19.
The global breathing disorder treatment market report would provide access to approx.: 45+ market data tables, 40+ figures and 200 (approximate) pages.
